Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ (NMS) NASDAQ (NMS) Primary 
3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY)
Harmony Biosciences (HRMY) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 27% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HRMY vs. ARGX: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes"
Harmony Biosciences (HRMY) could produce exceptional returns because of its solid growth attributes.
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HRMY vs. LQDA: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Liquidia Corporation (LQDA). But which of these two stocks presents investors with the better value opportunity right now?
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. ( HRMY ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Matthew Beck Jeffrey Dayno - President, CEO & Director Adam Zaeske - Executive VP & Chief Commercial Officer Kumar Budur - Executive VP and Chief Medical & Scientific Officer Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO Conference Call Participants Ami Fadia - Needham & Company, LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Danielle Brill Bongero - Truist Securities, Inc., Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Hoang - Deutsche Bank AG, Research Division Presentation Operator Good morning.
